Emerson Cell & Gene Tech Expo April 2026: Commercial Readiness

Modern life sciences manufacturing, particularly in the evolving cell and gene therapy sectors, requires a departure from traditional biotech approaches. The transition from clinical development to commercial scale demands a robust strategy for managing product and process knowledge to eliminate manual data entry and accelerate tech transfer. By prioritizing digital continuity, organizations can capture critical process parameters and quality attributes within reusable building blocks, reducing transfer timelines from months to minutes.

Effective digitalization involves deploying flexible automation and electronic workflows that scale from standalone operations to complex, integrated plant architectures. Real-time scheduling tools further enhance operational integrity by modeling "what-if" scenarios to manage bottlenecks and maintenance ripples. Ultimately, a unified data foundation allows for seamless integration of diverse sources, ensuring that batches are manufactured reliably and released faster. Explore these strategies to optimize your production orchestration and achieve sustainable, high-integrity manufacturing.